China Universal Asset Management Company’s Acrivon Therapeutics ACRV Stock Holding History

China Universal Asset Management Company’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,514	Closed	-$9.98K	–	498
2025 Q3	$9.98K	Sell	5,514 -784	-12%	-$1.1K	﹤0.01%	471
2025 Q2	$7.5K	Buy	6,298 +53	+0.8%	+$73	﹤0.01%	468
2025 Q1	$12.7K	Sell	6,245 -357	-5%	-$1.92K	﹤0.01%	470
2024 Q4	$39.7K	Buy	+6,602	New	+$48K	﹤0.01%	460

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

China Universal Asset Management Company's ACRV Position: Q4 2025 in Review

China Universal Asset Management Company sold out of Acrivon Therapeutics (ACRV) in Q4 2025, closing a stake of 5,514 shares — an estimated $9.98K sold.

China Universal Asset Management Company first reported a position in ACRV in Q4 2024 and held it in 4 quarters. The position peaked at $39.7K in Q4 2024. 48 funds tracked by Wall St. Rank hold ACRV as of Q4 2025.

China Universal Asset Management Company reported no remaining Acrivon Therapeutics position as of Q4 2025 after selling out during the quarter.
China Universal Asset Management Company sold 5,514 Acrivon Therapeutics shares in Q4 2025, an estimated $9.98K.
China Universal Asset Management Company first reported a position in Acrivon Therapeutics in Q4 2024 and held it in 4 quarters.
China Universal Asset Management Company's Acrivon Therapeutics position peaked at $39.7K in Q4 2024.
48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q4 2025.

Based on China Universal Asset Management Company's 13F filing for Q4 2025, filed 29 Jan 2026.